Experts Identify Serious Flaws in New Zealand's Smokefree 2025 Plan

Nov.18.2022
Experts Identify Serious Flaws in New Zealand's Smokefree 2025 Plan
Experts warn flaws in New Zealand government's plan to achieve smoke-free 2025 goal. Concerns about unrealistic assumptions in the model.

Experts working to reduce the harms of tobacco have discovered serious flaws in the New Zealand government's plan to achieve its smoke-free 2025 goal. Scholars from Australia and New Zealand, funded by the Ministry of Health, claim that the focus on 'denicotinization', or the simulation of tobacco without nicotine, will have the most significant impact.


The New Zealand government will allow ministers to achieve their 2025 targets by:


A significant reduction in the number of retail stores that can sell tobacco will make it illegal to sell the substance to anyone born after a specific date in order to foster a "smoke-free generation" by removing most of the nicotine from tobacco "to reduce its attractiveness and addictiveness." The government's model for this initiative is being reviewed by a group including Clive Bates, Ben Youdan, Ruth Bonita, George Laking, David Sweanor, and Robert Beaglehole, who have found "significant flaws" because "the model is based on a fundamental and flawed assumption that reducing nicotine in cigarettes compared with conventional practice will reduce smoking by 85% within five years." They continue by saying that "the assumptions that are used as key inputs to the model stem from a misinterpretation of a randomized controlled trial of smoking cessation interventions in New Zealand in 2009-10, which included very low nicotine content (VLNC) cigarettes.


They said that the issue lies in the fact that the relationship between the trial design and regulatory intervention for smoking cessation among the whole population is not significant. Their findings cannot be applied to legislative models, which include the fact that volunteers from e-cigarette clubs who have called the quit smoking hotline received medication and behavioral support, and the intervention group was also given free very low nicotine content cigarettes and instructed to smoke if they felt like it. The trial intervention only lasted for eight weeks and its impact was evaluated six months later.


This experiment does not account for the most likely reactions to measures aimed at reducing nicotine consumption, such as switching to electronic cigarettes, entering the larger illicit market, or finding alternative methods by consumers or manufacturers.


The author of the comment states that the model "made unsubstantiated assumptions based on a misunderstanding of the smoking cessation trial, in which the provision of nicotine-free cigarettes to people who have attempted to quit smoking was used as an enhanced standard cessation intervention.


It fails to reflect the current trends of government intervention in the form of nationwide regulation, which it was expected to represent.


It did not take into account the illicit trade of regular tobacco and other alternative methods, which could be significant and must be incorporated into any models for nicotine reduction measures.


For the purpose of decision-making, modeling of legislation should more accurately reflect the real-world processes involved (such as illegal trade, loopholes, and the shift towards electronic cigarettes), and place greater emphasis on the transparency of assumptions, sensitivity testing, and scenario analysis.


The organization suggested that the New Zealand government "reconsider its confidence in evaluating and analyzing the impacts of its policy to support the Cabinet's move towards nicotine-free initiatives.


Declaration:


This article is compiled from third-party information and is intended only for sharing and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content in the article. The translation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translator's abilities, there may be variations in the expression of the article compared to the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JT’s Ploom Volumes Rise 43.5% as Cigarettes Anchor Its Transition
JT’s Ploom Volumes Rise 43.5% as Cigarettes Anchor Its Transition
JT’s Ploom heated-tobacco volumes rose 43.5% in the first half of 2026, while combustibles still represented about 97% of its tobacco volume and remained the main earnings base. In Japan, reduced-risk products now account for 48.7% of industry shipments, shifting competition from category adoption towards brand share, pricing and consumer retention. JT’s results offer a revealing case of a traditional tobacco company pursuing a prolonged, dual-track transformation.
JTI
Jul.30
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
The UK High Court has ordered Chinese vape manufacturer Shenzhen SKE Technology to provide £569,039 ($776,000) in security for costs in its design infringement proceedings against Vapepen London and other defendants over its Crystal Bar vape product. The court did not accept the defendants’ main argument that recovering costs from a China-based company would face significant enforcement obstacles, but found that SKE had not sufficiently disclosed its own financial position. The order is procedural and does not determine the underlying infringement claims.
News
Aug.21
Putin Signs Russia’s Tobacco and Nicotine Product Licensing Law, Banning Unlicensed Sales From 2027
Putin Signs Russia’s Tobacco and Nicotine Product Licensing Law, Banning Unlicensed Sales From 2027
Russian President Vladimir Putin has signed a law introducing mandatory licensing for wholesale and retail trade in tobacco and nicotine-containing products, with the system taking effect on October 1, 2026, and unlicensed operations banned from March 1, 2027, while vape and e-liquid retail may also face uncertainty from temporary regional sales-ban powers.
Jul.01
Sesh touts independence, 8VC backing and retail reach as it challenges tobacco-owned pouch brands
Sesh touts independence, 8VC backing and retail reach as it challenges tobacco-owned pouch brands
U.S. nicotine pouch brand Sesh has emphasized its independence from Altria, Philip Morris International and British American Tobacco, along with backing from investors including 8VC, celebrity supporters and a retail footprint of more than 7,500 stores, as it seeks to differentiate itself in a market where major pouch brands are owned by large tobacco companies.
Regulations
Jul.07 by 2Firsts Perspectives
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
APUS has introduced the Chloe 50K disposable vape, which has appeared across U.S.-facing online retail channels including Element Vape and Vapesourcing. The device combines a purse-inspired body and chain attachment with a 20ml e-liquid capacity, 1,250mAh rechargeable battery, dual mesh coil, and battery and e-liquid indicators. It is rated for up to 50,000 puffs. The product does not appear on the FDA’s current list of authorized e-cigarettes, and U.S. retail availability does not indicate FDA marketing authorization.
Jul.15
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01